Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.
-
ICP-B794 has demonstrated superior anti-tumor activity in animal models, and exhibited significant tumor-killing effects even in large tumors.
-
Zurletrectinib demonstrated well-tolerated safety and promising antitumor activity in pediatric/adolescent patients with NTRK/ROS1-altered solid tumors.
-
InnoCare's HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with R/R MZL.
-
The first patient has been dosed in the registrational trial of InnoCare's BCL2 inhibitor mesutoclax for patients with BTK inhibitor treated MCL in China.